The National Cancer Institute (NCI) awarded a $672,844 five-year Project Grant (CFDA 93.395 - Cancer Treatment Research) to Northwestern University to conduct research on improving adoptive natural killer (NK) cell therapy for solid tumors. The key research aims are:
-
Determine the safe and effective dose of the anti-MIC antibody B10G5 in activating endogenous NK cells and reshaping the tumor microenvironment in canine soft tissue sarcomas, which serve as a predictive model for human undifferentiated pleomorphic sarcoma.
-
Optimize the adoptive transfer of NK cells for soft tissue sarcomas, evaluating how low-dose chemotherapy can promote persistence and proliferation of allogeneic and autologous NK cell products.
-
Investigate if the B10G5 antibody can act synergistically with adoptively transferred NK cells to effectively eliminate canine soft tissue sarcomas.
This research aims to develop improved combination therapies leveraging NK cell adoptive transfer and modulation of the tumor microenvironment, which could translate to more effective treatments for solid tumors in human patients.
Generated 3/25/25, 2:47 AM